Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721326 · ClinicalTrials.gov registry record · NA
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1,283
- Enrollment target
NCT05721326: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05721326 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,283 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05721326, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,283 participants
- Enrollment target
Study Summary
The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.
Primary Outcome
Scheduling and completion of genetic counseling appointments will be monitored through EHR. MPM stands for MyPennMedicine message which will be sent directly to the patient through the medical record.
Interventions
- OTHER Sequential EHR Communications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,283 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the finished NCT05721326 record still lists
NCT05721326 is an interventional study that assigns participants to a tested intervention. Its 1,283 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Sequential EHR Communications is the first listed.
NCT05721326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05721326 about?
NCT05721326 is a clinical study titled "Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition". The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and co...
What is the current status of trial NCT05721326?
This trial is currently completed. It is a NA study. The enrollment target is 1,283 participants. The study started on 2023-05-01. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05721326?
The interventions under investigation include: Sequential EHR Communications (OTHER).
Who is sponsoring clinical trial NCT05721326?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05721326's enrollment target sits among peer trials
1,283 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI